{"id":"47a329bf-613a-47cb-95d4-83fb5f57ed02","slug":"impact-of-the-revised-who-classification-of-diffuse-low-grade-glioma-on-clinical-decision-making-a-case-report","title":"Impact of the revised WHO classification of diffuse low-grade glioma on clinical decision making: A case report","authors":["Tim A. M. Bouwens van der Vlis","Ann Hoeben","Jan C. Beckervordersandforth","Linda Ackermans","Daniëlle B. P. Eekers","Rianne M. J. Wennekes","Olaf E. M. G. Schijns"],"abstract":"Background: In the 2016 update of the World Health Organization Classification of Tumors of the central nervous system, phenotypic and genotypic parameters are integrated in diffuse low-grade glioma (LGG) tumor classification. Implementation of this combined phenotypic–genotypic characterization identifies prognostic relevant subgroups. Case Description: We report a case of a 67-year-old patient with an LGG that showed molecular characteristics similar to glioblastoma multiforme (GBM). After gross total tumor resection, the patient received combination therapy (radiotherapy and chemotherapy) according to high-grade glioma treatment protocol. Conclusion: The introduction of molecular parameters to the classification of LGG will add a level of objectivity, which will yield biological homogeneous subclasses. Consequently, this will influence patient counseling and clinical decision making regarding treatment protocols.","thumbnailUrl":"https://sni-digital-videos.s3.amazonaws.com/articles/47a329bf-613a-47cb-95d4-83fb5f57ed02/featured/hero-1782420846431.png","publishDate":"2017-09-07T00:00:00.000Z","doi":"10.4103/sni.sni_166_17","categories":["Neuro-oncology","Case Report"],"fullTextUrl":"https://surgicalneurologyint.com/api/articles/47a329bf-613a-47cb-95d4-83fb5f57ed02/pdf"}